Holen Sie sich die Stockscreener-App
293.61
0.57%
-1.69
Handel nachbörslich:
293.61
Schlusskurs vom Vortag:
$295.30
Offen:
$296.79
24-Stunden-Volumen:
235.28K
Relative Volume:
0.62
Marktkapitalisierung:
$7.86B
Einnahmen:
$2.59B
Nettoeinkommen (Verlust:
$168.80M
KGV:
48.33
EPS:
6.0748
Netto-Cashflow:
$357.20M
1W Leistung:
+8.62%
1M Leistung:
-6.04%
6M Leistung:
-3.10%
1J Leistung:
+21.67%
1-Tages-Spanne:
$287.94
$299.32
1-Wochen-Bereich:
$270.00
$305.00
52-Wochen-Spanne:
$236.73
$343.12
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
293.61 | 8.05B | 2.59B | 168.80M | 357.20M | 6.0748 |
ABT
Abbott Laboratories
|
90.74 | 163.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
314.84 | 127.55B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.23 | 103.66B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
42.68 | 65.74B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.46 | 52.27B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Bio-Plex Pro Human Cytokine Assays from Bio-Radmultiplex panels for immune research - AD HOC NEWS
BIOBio-Rad Laboratories Inc Latest SEC Filings - Finviz
Bio Rad Laboratories (BIO) Following ddPCR Expansion Narrative Looks Fully Valued - Sahm
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Evaluating Growth Amidst Stable Price Movements - DirectorsTalk Interviews
Oxidative Stress Assay Market Size to Reach USD 3.25 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (LSX:862449) - TradingView
Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (FWB:BUW) - TradingView
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 6.5% Rally? GF Value Says Undervalued - GuruFocus
Bio-Rad rises as life-science tools deal activity and activist interest appear to lift sentiment - Quiver Quantitative
Bio-Rad Laboratories, Inc. Class A Actuals & Estimates (NYSE:BIO) - TradingView
Bio-Rad Laboratories Jumps 5.6% Amid Sector-Wide Rally - AlphaStreet
BIO Forecast — Price Target — Prediction for 2027 - TradingView
Lyme Disease Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Abbott, Bio-Rad Labs, Covance Inc.F. Hoffmann-La Roche AG, T2 Biosystems - Barchart.com
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? - AOL.com
Bio Rad Laboratories Inc (BIOb) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
2x Valuation Gap: BIO vs. CRL — Who’s Wrong? - NAI500
Bio Rad Laboratories Inc (BIO) Institutional Confidence - TradingKey
Why Bio-Rad’s Bio-Plex Pro Human Cytokine Screening Panel still matters in the lab - AD HOC NEWS
Bio Rad Laboratories Inc (BIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bio Rad Laboratories Inc (BIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bio Rad Laboratories Inc (BIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio Rad Laboratories Inc (BIOb) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bio Rad Laboratories Inc (BIOb) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bio Rad Laboratories Inc (BIOb) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bio Rad Laboratories Inc (BIOb) Institutional Confidence - TradingKey
Bio Rad Laboratories Inc (BIOb) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bio Rad Laboratories Inc (BIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bio Rad Laboratories Inc (BIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bio Rad Laboratories Inc (BIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bio Rad Laboratories Inc (BIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bio Rad Laboratories Inc (BIOb) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio Rad Laboratories Inc (BIOb) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bio Rad Laboratories Inc (BIOb) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
From Concept To Cure: Using AAV In Gene Therapy - Pharmaceutical Online
(BIO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
In Fight With GC, Bio-Rad Adds Quinn Emanuel to Legal Team - Law.com
Bio-Rad Receives MicroVal Validation for Two EZ-Check Listeria Testing Kits - Quality Assurance & Food Safety
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Limited Upside Amid a Competitive Landscape - DirectorsTalk Interviews
Bio-Rad receives MicroVal validation for EZ-Check™ Listeria testing kits - News-Medical
Elliott builds big stake in life-science firm Bio-Rad Labs, WSJ reports - MSN
Bio Rad Laboratories Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
In Vitro Diagnostic (IVD) Quality Control Market Overview, Key - openPR.com
(BIO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
BioRad Listeria Test Kits Receive MicroVal Certification - Food Safety Magazine
Bio-Rad receives microVal validation for EZ-CheckTM Listeria spp. and EZ-Check Listeria monocytogenes Testing Kits - Cambridge Network
Bio-Rad (BIO) Q1 2026 Earnings Transcript - AOL.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Tight Market with Strategic Growth Potential - DirectorsTalk Interviews
IVD Quality Control Market Size, Share | Industry Report [2034] - Fortune Business Insights
Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching - 富途牛牛
Bio-Rad Is a Strategic Investor in Sartorius, With Around $5B Stake -- WSJ - Moomoo
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):